FlowCell
Alan K. Hauser is a PrecisionCare executive championing life-sciences Innovation-to-Commercialization (I2C) by translating the promise of emerging proprietary multi-omic platforms into practice. Dr. Hauser has over three decades of experience in technical, intellectual, property, market, and business development aspects of commercializing drug-discovery and diagnostics inventions.
Dr. Hauser co-invented four U.S. patents covering microfluidic bio tools and launched nine drug-discovery and DNA diagnostic products. This resulted in two initial public offerings that include a Silicon Valley lab-on-a-chip venture of $180 million IPO. Five of these companies have acquired totaling over $1.8 billion. Dr. Hauser led an I2C team that focused on biomarker-enabled companion diagnostics acquiring $150 million of IP-powered revenue per year. His experience in stratified medicine is particularly relevant to the mission of FlowCell and Fluids for Life.
This person is not in any offices
FlowCell
Microfluidics solutions for biologists seeking to increase physiological relevance of their experiments by enabling perfusion for control of cellular microenvironment or dosing of drugs, as well as specialized seeding for 3D cultures: spheroids, organoids and tumoroids.